Key Details
Price
$28.40Last Dividend
$0.03Annual ROE
-10.84%Beta
1.07Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 09, 2015Next split:
N/ARecent split:
Dec 28, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections.
Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Daniel Stauder - JMP Securities Suraj Kalia - Oppenheimer Nelson Cox - Lake Street Capital Mike Matson - Needham & Company Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Third Quarter 2024 Financial Conference Call. At this time, all participants are in listen only mode.
Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at the Lotte New York Palace.
5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfusion Resolution in 90% of Affected Subjects Post-AMDS Implantation 1-Year Data from the NEOS Study Indicate E-vita Open Neo is Safe and Effective in the Treatment of Aortic Arch Pathologies with Low Combined Major Adverse Events Rate ATLANTA , Oct. 10, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS DARTS and PERSEVERE trials and E-vita Open Neo study presented in Late-Breaking Science presentations at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon, Portugal. The presentation regarding the AMDS DARTS trial highlighted 5-year aortic remodeling data that demonstrate positive, durable patient outcomes following AMDS implantation.
Artivion (AORT) reported quarterly earnings of $0.06 per share, surpassing the Zacks Consensus Estimate of $0.02 per share. This represents an increase from earnings of $0.02 per share in the same quarter last year.
Here is the performance of Artivion (AORT) and Cencora (COR) compared to their sector in the current year.
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.
FAQ
- What is the primary business of Artivion?
- What is the ticker symbol for Artivion?
- Does Artivion pay dividends?
- What sector is Artivion in?
- What industry is Artivion in?
- What country is Artivion based in?
- When did Artivion go public?
- Is Artivion in the S&P 500?
- Is Artivion in the NASDAQ 100?
- Is Artivion in the Dow Jones?
- When was Artivion's last earnings report?
- When does Artivion report earnings?
- Should I buy Artivion stock now?